Enjoy complimentary customisation on priority with our Enterprise License!
The immunosuppressants market size is forecast to increase by USD 4.48 billion, at a CAGR of 5.19% between 2023 and 2028. Kidney transplantation is a life-saving medical procedure for individuals suffering from end-stage renal disease. However, the high cost of this treatment, including the transplant itself and subsequent medications and follow-up care, can be a significant barrier for many patients. Reimbursement policies play a crucial role in making kidney transplantation more accessible. Despite this, the rising prevalence of autoimmune diseases and increasing road accidents leading to organ damage necessitates a greater focus on increasing organ donations and improving transplantation procedures. Effective reimbursement policies can incentivize organ donation, streamline the transplantation process, and reduce financial burden on patients. By addressing the financial challenges associated with kidney transplantation, we can ensure more people have access to this vital treatment and ultimately improve overall healthcare outcomes.
For More Highlights About this market report, Request Free Sample
The market is primarily driven by the increasing number of organ transplantations and the need to prevent the immune response from rejecting the transplanted organ. Immunosuppressants are essential in clinical immunosuppression, used during both induction therapy and maintenance therapy to suppress the immune system and prevent acute rejection response. Autoimmune diseases such as Myasthenia gravis, Arthritis, Lupus, Rheumatoid arthritis, Crohn's disease, and Systemic autoimmune diseases including Systemic lupus erythematosus, Scleroderma, Psoriasis, and Dermatomyositis, also contribute significantly to the market growth. Key players in the Immunosuppressants market include GlaxoSmithKline with its drug Benlysta, used for the treatment of Lupus nephritis. Regulatory processes and regulatory approvals also play a crucial role in the market. For instance, Aurinia Pharmaceuticals' Lupus nephritis drug, Voclosporin, received FDA approval in 2019. The market is expected to witness significant growth due to the increasing prevalence of autoimmune diseases and the need for effective treatments.
Reimbursement policies for kidney transplantation is notably driving market growth. Chronic kidney disease (CKD) is a significant health issue in the United States, affecting over 25 million Americans and resulting in more deaths than prostate cancer or breast cancer. Approximately 675,000 Americans have irreversible CKD or end-stage renal disease, necessitating kidney transplantation. The National Kidney Foundation, in collaboration with the US National Congress and other organizations, is advocating for organ transplantation as a priority due to the rising burden of CKD. Immunosuppressants play a crucial role in organ transplants by preventing the rejection of the transplanted organ. MDPI, a leading open-access scientific journal, has published numerous studies on immunosuppressants and their use in transplantation.
Further, notable companies in the immunosuppressants market include GlaxoSmithKline, which offers Benlysta for the treatment of lupus nephritis, and Aurinia Pharmaceuticals, which has received product approval for voclosporin to treat adults with focal segmental glomerulosclerosis and IgA nephropathy. Regulatory processes are essential in ensuring the safety and efficacy of these treatments for systemic autoimmune diseases such as systemic lupus erythematosus, scleroderma, psoriasis, and dermatomyositis. Thus, such factors are driving the growth of the market during the forecast period.
High dependency on immunosuppressants for kidney transplantation is the key trend in the market. The Immunosuppressants market holds significance in the context of organ transplants, particularly in the treatment of kidney transplant rejection. The MDPI journal reports that kidney transplantation is becoming increasingly common due to advancements in surgical techniques and healthcare services. However, the immune system's response to the transplanted organ can lead to rejection. Three types of rejection exist: hyperacute, acute, and chronic. Hyperacute rejection occurs immediately post-transplant due to incompatible antigens.
Further, glaxoSmithKline's Benlysta is an approved immunosuppressant for the treatment of lupus nephritis, a type of systemic autoimmune disease. Regulatory processes are crucial in product approval for immunosuppressants used in the treatment of various conditions, such as lupus nephritis, scleroderma, psoriasis, and dermatomyositis. Aurinia Pharmaceuticals' Lupkynis is another approved immunosuppressant for lupus nephritis treatment. Immunosuppressants play a vital role in preventing the immune system from rejecting transplanted organs and enabling successful transplantation. Thus, such trends will shape the growth of the market during the forecast period.
Side effects of immunosuppressants is the major challenge that affects the growth of the market. Immunosuppressants play a crucial role in the treatment of organ transplants, particularly in preventing the immune system from rejecting the transplanted organ. MDPI reports that various immunosuppressants have received product approval for use in kidney transplantation therapy. Notable companies, such as GlaxoSmithKline, have developed and marketed effective immunosuppressants like Benlysta, which is indicated for the treatment of lupus nephritis, a systemic autoimmune disease. However, the use of immunosuppressants comes with side effects, including diarrhea, increased risk of infections, nausea, and vomiting, which can significantly impact patients' adherence to treatment.
Additionally, immunosuppressants can cause muscle damage, leading to decreased muscle function. Regulatory processes ensure the safety and efficacy of these drugs, and ongoing research focuses on developing new immunosuppressants for conditions like scleroderma, psoriasis, and dermatomyositis. Aurinia Pharmaceuticals, for instance, is currently investigating the potential of voclosporin for the treatment of nephrotic syndrome in patients with focal segmental glomerulosclerosis. Hence, the above factors will impede the growth of the market during the forecast period
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market forecast report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The corticosteroids segment is estimated to witness significant growth during the forecast period. Immunosuppressants play a crucial role in organ transplantation and the management of autoimmune diseases. These medications suppress the immune response to prevent the rejection of transplanted organs and to manage conditions such as myasthenia gravis, arthritis, lupus, rheumatoid arthritis, Crohn's disease, and multiple sclerosis. Corticosteroids, including prednisone, are commonly used for both induction and maintenance therapy. They act by reducing the production of cytokines and vasoactive substances, such as interleukin-1, interleukin-2, interleukin-6, tumor necrosis factor-alpha, chemokines, prostaglandins, and proteases.
Get a glance at the market share of various regions Download the PDF Sample
The corticosteroids segment accounted for USD 5.58 billion in 2018. Other immunosuppressant drug classes include monoclonal antibodies, calcineurin inhibitors, mTOR inhibitors, and anti-proliferative agents. Developing economies are witnessing an increasing demand for these drugs due to the growing number of organ transplant activities and waitlisted patients. Keywords: Organ transplantation, Immune response, Autoimmune diseases, Myasthenia gravis, Arthritis, Lupus, Rheumatoid arthritis, Crohn's disease, Kidney transplant, Liver transplant, Heart transplant, Clinical immunosuppression, Induction therapy, Maintenance therapy, Acute rejection response, Autoimmune disorders, Multiple sclerosis, Alopecia areata, Organ transplant procedures, Organ donors, Tissue engineering, Implants, Developing economies, Drug class, Corticosteroids, Monoclonal antibodies, Calcineurin inhibitors, mTOR inhibitors, Anti-proliferative agents, Hospital pharmacies, Retail pharmacies, Online pharmacies, Cyclosporine, Tacrolimus, Indication, Non-autoimmune inflammatory diseases, Artificial organs, PubMed Central, Transplant activity, Waitlisted patient.
For more insights on the market share of various regions Download PDF Sample now!
Europe is estimated to contribute 33% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. Immunosuppressants are essential medications used in organ transplantation to suppress the immune response and prevent rejection of the transplanted organ. These drugs are also indicated for the treatment of autoimmune disorders such as myasthenia gravis, arthritis, lupus, rheumatoid arthritis, Crohn's disease, and multiple sclerosis. Immunosuppressants work by suppressing the immune system, allowing the transplanted organ or tissue to integrate without being attacked. Clinical immunosuppression is initiated through induction therapy during organ transplant procedures, followed by maintenance therapy to prevent acute rejection response. Immunosuppressant drug classes include corticosteroids, monoclonal antibodies, calcineurin inhibitors, mTOR inhibitors, and anti-proliferative agents.
Further, the global immunosuppressants market is driven by the increasing number of organ transplant procedures, organ donors, and tissue engineering and implants. Developing economies are expected to provide significant growth opportunities due to the increasing prevalence of autoimmune disorders and non-autoimmune inflammatory diseases. PubMed Central reports a growing transplant activity and a significant increase in the number of waitlisted patients, further fueling the demand for immunosuppressants. Key challenges include the side effects of long-term immunosuppression and the high cost of these medications. Artificial organs and advances in transplant technology are expected to offer new opportunities in the market.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD Billion " for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
You may also interested in below market reports:
Immunosuppressants market overview and applications in organ transplantation and autoimmune diseases immunosuppressants are a class of drugs used to suppress the immune response, making it possible for the body to accept transplanted organs or tissues. In organ transplantation, immunosuppressants play a crucial role in preventing acute rejection response, allowing successful grafting of kidneys, livers, and hearts. Induction therapy and maintenance therapy are common methods used in clinical immunosuppression .Immunosuppressants are also used in managing autoimmune disorders such as Myasthenia gravis, Arthritis, Lupus, Rheumatoid arthritis, Crohn's disease, Multiple sclerosis, and Alopecia areata. These conditions involve the immune system attacking the body's own tissues.
Moreover, the global immunosuppressants market is segmented based on drug class, including Corticosteroids, Monoclonal antibodies, Calcineurin inhibitors, mTOR inhibitors, and Anti-proliferative agents. The market caters to various channels such as hospital pharmacies, retail pharmacies, and online pharmacies. Immunosuppressants are essential in organ transplant procedures, where the availability of organ donors and transplant activity significantly impacts the market. Developing economies are expected to witness a surge in demand due to increasing transplant procedures and rising awareness about organ donation. PubMed Central provides extensive research on the use and impact of immunosuppressants in organ transplantation and autoimmune diseases.
Further, key players in the market include Cyclosporine and Tacrolimus. Indication-wise, the market is further segmented into organ transplant procedures and non-autoimmune inflammatory diseases. The market for immunosuppressants is also influenced by the development of artificial organs and implants. In conclusion, the immunosuppressants market holds immense potential due to its applications in organ transplantation and managing autoimmune disorders. The market is expected to grow significantly due to the increasing number of transplant procedures, rising awareness about organ donation, and advancements in drug development.
Market Scope |
|
Report Coverage |
Details |
Page number |
138 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.19% |
Market growth 2024-2028 |
USD 4.48 billion |
Market structure |
Concentrated |
YoY growth 2023-2024(%) |
4.91 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
Europe at 33% |
Key countries |
US, Germany, China, UK, and Canada |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., Accord Healthcare Ltd., Astellas Pharma Inc., Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Intas Pharmaceuticals Ltd., Johnson and Johnson Services Inc., Novartis AG, Pfizer Inc., RPG Life Sciences Ltd., Sanofi SA, Sebela Pharmaceuticals Inc., and Viatris Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Drug Class
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.